Merck & Co., Inc.: Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS =1)
Opinion Granted Based on Positive Results From Phase 3 KEYNOTE-826 Trial Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency's Committee
Source: finanznachrichten.de
